Biomea Fusion Inc Earnings
The next earnings date for Biomea Fusion Inc has not yet been scheduled.
Analyst Estimates of Biomea Fusion Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Biomea Fusion Inc Earnings: Historical
| 08/05/2026 | After Market | $-0.12 | 42.86% |
| 05/11/2026 | After Market | $-0.17 | 10.53% |
| 03/25/2026 | --- | $-0.12 | 45.61% |
| 11/04/2025 | After Market | $-0.24 | 17.24% |
| 08/05/2025 | After Market | $-0.51 | 0.00% |
| 05/05/2025 | After Market | $-0.80 | -33.33% |
| 03/31/2025 | --- | $-0.81 | 11.18% |
| 10/29/2024 | After Market | $-0.91 | 0.00% |
| 07/31/2024 | After Market | $-1.03 | 5.50% |
| 05/02/2024 | After Market | $-1.09 | -17.20% |
More About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
“Biomea Fusion Inc Earnings” Can Refer to the Biomea Fusion Inc Earnings Date
Some people say “Biomea Fusion Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Biomea Fusion Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Biomea Fusion Inc Stock on the Earnings Date
If you own Biomea Fusion Inc stock (BMEA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Biomea Fusion Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Biomea Fusion Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Biomea Fusion Inc Earnings
You can contact us any time if you would like to ask questions about Biomea Fusion Inc earnings or anything else related to the stock market.